
-
Vanda Pharmaceuticals Inc. NasdaqGM:VNDA Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Location: 2200 Pennsylvania Avenue NW, Washington, DC, 20037, United States | Website: https://www.vandapharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-70.44M
Cash
340.9M
Avg Qtr Burn
-14.12M
Short % of Float
9.28%
Insider Ownership
6.66%
Institutional Own.
77.66%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HETLIOZ® (tasimelteon) Details SMS (Smith-Magenis Syndrome) | Approved Quarterly sales | |
Fanapt® (iloperidone) Details Mental health, Bipolar depression, Bipolar disease | Approved Quarterly sales | |
Fanapt® (iloperidone) Details Schizophrenia and PDP (Parkinson's disease psychosis) | Approved Quarterly sales | |
HETLIOZ® (tasimelteon) Details Non-24-Hour Sleep-Wake Disorder (Non-24) | Approved Quarterly sales | |
PONVORY® (ponesimod) Details Multiple sclerosis | Approved Quarterly sales | |
Bysanti™ (milsaperidone) Details Schizophrenia, Mental health, Bipolar disease | PDUFA Approval decision | |
HETLIOZ® (tasimelteon) Details Insomnia | sNDA Resubmission | |
HETLIOZ® (tasimelteon) Details Jet Lag | sNDA FDA meeting | |
Tradipitant Details Motion sickness | NDA Acceptance for review | |
Tradipitant Details Gastroparesis | NDA Resubmission | |
Bysanti™ (milsaperidone) Details Mental Health, Major depressive disorder | Phase 3 Data readout | |
VQW-765 Details Social Anxiety Disorder | Phase 3 Initiation | |
VSJ-110 Details Dry eye disease | Phase 2 Data readout | |
Trichostatin A (VTR-297) Details Onychomycosis, Fungal infections | Phase 1 Data readout | |
VCA-894A Details Charcot-Marie-Tooth disease, axonal, type 2S , Neuropathy | Phase 1 Initiation | |
Failed Discontinued | ||
Tradipitant Details Atopic pruritus , Atopic dermatitis | Failed Discontinued | |
Trichostatin A (VTR-297) Details Leukemia, Multiple myeloma, Lymphoma | Failed Discontinued |